Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

MDXG vs APOG

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
MDXG
MiMedx Group, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$548M
5Y Perf.+2.8%
APOG
Apogee Enterprises, Inc.

Construction

IndustrialsNASDAQ • US
Market Cap$787M
5Y Perf.+77.1%

MDXG vs APOG — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
MDXG logoMDXG
APOG logoAPOG
IndustryBiotechnologyConstruction
Market Cap$548M$787M
Revenue (TTM)$389M$1.40B
Net Income (TTM)$31M$54M
Gross Margin81.0%22.7%
Operating Margin10.2%6.7%
Forward P/E295.2x10.6x
Total Debt$23M$286M
Cash & Equiv.$166M$40M

MDXG vs APOGLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

MDXG
APOG
StockMay 20May 26Return
MiMedx Group, Inc. (MDXG)100102.8+2.8%
Apogee Enterprises,… (APOG)100177.1+77.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: MDXG vs APOG

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDXG leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Apogee Enterprises, Inc. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
MDXG
MiMedx Group, Inc.
The Income Pick

MDXG carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • beta 1.22
  • Rev growth 20.0%, EPS growth 14.3%, 3Y rev CAGR 16.1%
  • Lower volatility, beta 1.22, Low D/E 8.8%, current ratio 4.32x
Best for: income & stability and growth exposure
APOG
Apogee Enterprises, Inc.
The Long-Run Compounder

APOG is the clearest fit if your priority is long-term compounding.

  • 10.5% 10Y total return vs MDXG's -48.5%
  • Lower P/E (10.6x vs 295.2x)
  • 2.8% yield; 14-year raise streak; the other pay no meaningful dividend
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthMDXG logoMDXG20.0% revenue growth vs APOG's 3.2%
ValueAPOG logoAPOGLower P/E (10.6x vs 295.2x)
Quality / MarginsMDXG logoMDXG7.9% margin vs APOG's 3.9%
Stability / SafetyMDXG logoMDXGBeta 1.22 vs APOG's 1.25, lower leverage
DividendsAPOG logoAPOG2.8% yield; 14-year raise streak; the other pay no meaningful dividend
Momentum (1Y)APOG logoAPOG-2.8% vs MDXG's -47.1%
Efficiency (ROA)MDXG logoMDXG9.7% ROA vs APOG's 4.8%, ROIC 42.3% vs 8.1%

MDXG vs APOG — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

MDXGMiMedx Group, Inc.
FY 2025
Surgical
100.0%$142M
APOGApogee Enterprises, Inc.
FY 2026
Architectural Metals Segment
35.4%$504M
Architectural Services segment
30.8%$439M
Architectural
19.9%$284M
Performance Surfaces
13.9%$198M

MDXG vs APOG — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMDXGLAGGINGAPOG

Income & Cash Flow (Last 12 Months)

MDXG leads this category, winning 4 of 6 comparable metrics.

APOG is the larger business by revenue, generating $1.4B annually — 3.6x MDXG's $389M. Profitability is closely matched — net margins range from 7.9% (MDXG) to 3.9% (APOG). On growth, APOG holds the edge at +1.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricMDXG logoMDXGMiMedx Group, Inc.APOG logoAPOGApogee Enterprise…
RevenueTrailing 12 months$389M$1.4B
EBITDAEarnings before interest/tax$53M$57M
Net IncomeAfter-tax profit$31M$54M
Free Cash FlowCash after capex$66M$95M
Gross MarginGross profit ÷ Revenue+81.0%+22.7%
Operating MarginEBIT ÷ Revenue+10.2%+6.7%
Net MarginNet income ÷ Revenue+7.9%+3.9%
FCF MarginFCF ÷ Revenue+17.0%+6.8%
Rev. Growth (YoY)Latest quarter vs prior year-33.1%+1.6%
EPS Growth (YoY)Latest quarter vs prior year-2.4%+6.1%
MDXG leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

Evenly matched — MDXG and APOG each lead in 3 of 6 comparable metrics.

At 11.5x trailing earnings, MDXG trades at a 21% valuation discount to APOG's 14.5x P/E. On an enterprise value basis, MDXG's 5.1x EV/EBITDA is more attractive than APOG's 21.9x.

MetricMDXG logoMDXGMiMedx Group, Inc.APOG logoAPOGApogee Enterprise…
Market CapShares × price$548M$787M
Enterprise ValueMkt cap + debt − cash$405M$1.0B
Trailing P/EPrice ÷ TTM EPS11.53x14.52x
Forward P/EPrice ÷ next-FY EPS est.295.20x10.64x
PEG RatioP/E ÷ EPS growth rate0.43x
EV / EBITDAEnterprise value multiple5.14x21.95x
Price / SalesMarket cap ÷ Revenue1.31x0.56x
Price / BookPrice ÷ Book value/share2.15x1.53x
Price / FCFMarket cap ÷ FCF7.51x8.27x
Evenly matched — MDXG and APOG each lead in 3 of 6 comparable metrics.

Profitability & Efficiency

MDXG leads this category, winning 8 of 9 comparable metrics.

MDXG delivers a 12.9% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $11 for APOG. MDXG carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to APOG's 0.56x. On the Piotroski fundamental quality scale (0–9), APOG scores 7/9 vs MDXG's 5/9, reflecting strong financial health.

MetricMDXG logoMDXGMiMedx Group, Inc.APOG logoAPOGApogee Enterprise…
ROE (TTM)Return on equity+12.9%+10.8%
ROA (TTM)Return on assets+9.7%+4.8%
ROICReturn on invested capital+42.3%+8.1%
ROCEReturn on capital employed+25.7%+9.7%
Piotroski ScoreFundamental quality 0–957
Debt / EquityFinancial leverage0.09x0.56x
Net DebtTotal debt minus cash-$144M$247M
Cash & Equiv.Liquid assets$166M$40M
Total DebtShort + long-term debt$23M$286M
Interest CoverageEBIT ÷ Interest expense25.32x5.97x
MDXG leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

APOG leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in APOG five years ago would be worth $11,292 today (with dividends reinvested), compared to $3,712 for MDXG. Over the past 12 months, APOG leads with a -2.8% total return vs MDXG's -47.1%. The 3-year compound annual growth rate (CAGR) favors APOG at -0.0% vs MDXG's -14.1% — a key indicator of consistent wealth creation.

MetricMDXG logoMDXGMiMedx Group, Inc.APOG logoAPOGApogee Enterprise…
YTD ReturnYear-to-date-43.1%-1.3%
1-Year ReturnPast 12 months-47.1%-2.8%
3-Year ReturnCumulative with dividends-36.6%-0.1%
5-Year ReturnCumulative with dividends-62.9%+12.9%
10-Year ReturnCumulative with dividends-48.5%+10.5%
CAGR (3Y)Annualised 3-year return-14.1%-0.0%
APOG leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — MDXG and APOG each lead in 1 of 2 comparable metrics.

MDXG is the less volatile stock with a 1.22 beta — it tends to amplify market swings less than APOG's 1.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. APOG currently trades 73.2% from its 52-week high vs MDXG's 46.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricMDXG logoMDXGMiMedx Group, Inc.APOG logoAPOGApogee Enterprise…
Beta (5Y)Sensitivity to S&P 5001.22x1.25x
52-Week HighHighest price in past year$7.99$49.99
52-Week LowLowest price in past year$3.02$30.75
% of 52W HighCurrent price vs 52-week peak+46.2%+73.2%
RSI (14)Momentum oscillator 0–10049.353.6
Avg Volume (50D)Average daily shares traded1.4M253K
Evenly matched — MDXG and APOG each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates MDXG as "Buy" and APOG as "Hold". Consensus price targets imply 171.0% upside for MDXG (target: $10) vs 92.7% for APOG (target: $71). APOG is the only dividend payer here at 2.83% yield — a key consideration for income-focused portfolios.

MetricMDXG logoMDXGMiMedx Group, Inc.APOG logoAPOGApogee Enterprise…
Analyst RatingConsensus buy/hold/sellBuyHold
Price TargetConsensus 12-month target$10.00$70.50
# AnalystsCovering analysts156
Dividend YieldAnnual dividend ÷ price+2.8%
Dividend StreakConsecutive years of raises14
Dividend / ShareAnnual DPS$1.04
Buyback YieldShare repurchases ÷ mkt cap+0.6%+1.9%
Insufficient data to determine a leader in this category.
Key Takeaway

MDXG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). APOG leads in 1 (Total Returns). 2 tied.

Best OverallMiMedx Group, Inc. (MDXG)Leads 2 of 6 categories
Loading custom metrics...

MDXG vs APOG: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is MDXG or APOG a better buy right now?

For growth investors, MiMedx Group, Inc.

(MDXG) is the stronger pick with 20. 0% revenue growth year-over-year, versus 3. 2% for Apogee Enterprises, Inc. (APOG). MiMedx Group, Inc. (MDXG) offers the better valuation at 11. 5x trailing P/E (295. 2x forward), making it the more compelling value choice. Analysts rate MiMedx Group, Inc. (MDXG) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — MDXG or APOG?

On trailing P/E, MiMedx Group, Inc.

(MDXG) is the cheapest at 11. 5x versus Apogee Enterprises, Inc. at 14. 5x. On forward P/E, Apogee Enterprises, Inc. is actually cheaper at 10. 6x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — MDXG or APOG?

Over the past 5 years, Apogee Enterprises, Inc.

(APOG) delivered a total return of +12. 9%, compared to -62. 9% for MiMedx Group, Inc. (MDXG). Over 10 years, the gap is even starker: APOG returned +10. 5% versus MDXG's -48. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — MDXG or APOG?

By beta (market sensitivity over 5 years), MiMedx Group, Inc.

(MDXG) is the lower-risk stock at 1. 22β versus Apogee Enterprises, Inc. 's 1. 25β — meaning APOG is approximately 3% more volatile than MDXG relative to the S&P 500. On balance sheet safety, MiMedx Group, Inc. (MDXG) carries a lower debt/equity ratio of 9% versus 56% for Apogee Enterprises, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — MDXG or APOG?

By revenue growth (latest reported year), MiMedx Group, Inc.

(MDXG) is pulling ahead at 20. 0% versus 3. 2% for Apogee Enterprises, Inc. (APOG). On earnings-per-share growth, the picture is similar: MiMedx Group, Inc. grew EPS 14. 3% year-over-year, compared to -35. 2% for Apogee Enterprises, Inc.. Over a 3-year CAGR, MDXG leads at 16. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — MDXG or APOG?

MiMedx Group, Inc.

(MDXG) is the more profitable company, earning 11. 6% net margin versus 3. 9% for Apogee Enterprises, Inc. — meaning it keeps 11. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDXG leads at 15. 3% versus 6. 0% for APOG. At the gross margin level — before operating expenses — MDXG leads at 82. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is MDXG or APOG more undervalued right now?

On forward earnings alone, Apogee Enterprises, Inc.

(APOG) trades at 10. 6x forward P/E versus 295. 2x for MiMedx Group, Inc. — 284. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MDXG: 171. 0% to $10. 00.

08

Which pays a better dividend — MDXG or APOG?

In this comparison, APOG (2.

8% yield) pays a dividend. MDXG does not pay a meaningful dividend and should not be held primarily for income.

09

Is MDXG or APOG better for a retirement portfolio?

For long-horizon retirement investors, Apogee Enterprises, Inc.

(APOG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 25), 2. 8% yield). Both have compounded well over 10 years (APOG: +10. 5%, MDXG: -48. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between MDXG and APOG?

These companies operate in different sectors (MDXG (Healthcare) and APOG (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MDXG is a small-cap high-growth stock; APOG is a small-cap deep-value stock. APOG pays a dividend while MDXG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

MDXG

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

APOG

Income & Dividend Stock

  • Sector: Industrials
  • Market Cap > $100B
  • Gross Margin > 13%
  • Dividend Yield > 1.1%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform MDXG and APOG on the metrics below

Revenue Growth>
%
(MDXG: -33.1% · APOG: 1.6%)
Net Margin>
%
(MDXG: 7.9% · APOG: 3.9%)
P/E Ratio<
x
(MDXG: 11.5x · APOG: 14.5x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.